2016
DOI: 10.18632/aging.101037
View full text |Buy / Rent full text
|
Sign up to set email alerts
|

Abstract: Tripartite motif-containing 24 (TRIM24), a member of the transcription intermediary factor 1 family, is defined as a co-regulator with several nuclear receptors, such as RARα. TRIM24 has been reported to be involved in many cancers. In this study, we aimed to investigate the expression pattern and prognostic significance of TRIM24 and its relationship with RARα in esophageal squamous cell cancer (ESCC). Both mRNA and protein expression levels of TRIM24 were found to be significantly decreased in ESCC, as judge… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

2
14
0

Year Published

2018
2018
2020
2020

Publication Types

Select...
4

Relationship

1
3

Authors

Journals

citations
Cited by 11 publications
(54 citation statements)
references
References 36 publications
(54 reference statements)
2
14
0
Order By: Relevance
“…In clinical practice, many oncologists have realized that the TNM staging system alone does not have the optimal predictive value in several human cancers, including ESCC [7,38,39], consistent with our findings. Consequently, additional prognostic biomarkers are required to improve the risk assessment of the TNM staging system.…”
Section: Discussionsupporting
confidence: 89%
See 1 more Smart Citation
“…In clinical practice, many oncologists have realized that the TNM staging system alone does not have the optimal predictive value in several human cancers, including ESCC [7,38,39], consistent with our findings. Consequently, additional prognostic biomarkers are required to improve the risk assessment of the TNM staging system.…”
Section: Discussionsupporting
confidence: 89%
“…The mortality rates of ESCC have begun to decline due to recent advances in diagnostic and therapeutic techniques, but the 5-year overall survival (OS) for patients with resectable ESCC is only 35-45%, which is still dismal [5,6]. This can likely be explained by the inability of the TNM staging system to accurately predict the prognosis of patients with resectable ESCC [7]. Some patients with early-stage ESCC rapidly develop local and regional recurrences and distant metastases after esophagectomy [8].…”
Section: Introductionmentioning
confidence: 99%
“…Although promising progress has been attained in treating esophageal cancer, it responds poorly to chemotherapeutic drugs and the mortality still remains high [ 51 , 55 , 56 , 57 , 58 , 59 ]. Surgery, chemotherapy and radiotherapy are the most widely-used treatment methods but about half of advanced esophageal cancer cases result in recurrence and patients normally succumb to resistant disease [ 60 , 61 , 62 , 63 , 64 ]. There is a lack of understanding of the mechanisms driving the initiation, progression and the occurrence of refractory disease.…”
Section: Introductionmentioning
confidence: 99%
“…11 Chi et al showed that TRIM24 was a potential predictor of survival in EC patients. 12 The research by Wen J et al suggested that pretreatment gene expression analysis could help predict the response to concurrent chemoradiotherapy in ESCC patients, thus facilitating individualized treatment of tumor patients. 13 However, the acquisition of these genes and factors requires accurate detection instruments and complex detection procedures, which are difficult to obtain in general hospitals.…”
Section: Introductionmentioning
confidence: 99%